The monoclonal antibody revolution has produced a wave of important new therapeutics, but developing effective antibodies remains elusive for many targets and indications. The discovery and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on ...

Katelyn is a writer with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...

Forbes contributors publish independent expert analyses and insights. Barry Collins is a tech journalist writing about PCs, Macs and games. Serif’s Affinity suite – a powerful rival to Adobe’s ...